After hard work, I’m proud to share our newly published Cochrane meta-analysis! 🔍 Adjuvant EGFR-TKIs for resected stage I–III EGFR-mutant NSCLC: what does the evidence really say? cochranelibrary.com/cdsr/doi/10.10… Cochrane Martina Imbimbo Roberto Ferrara Vittorio Simeon giuseppe viscardi

🆕 #ASCO25 🆙 ☑️#LCSM Poster 🔥SOLARA: Phase 1/2, FIH study of BH-30643 in pts with NSCLC harboring EGFR and/or HER2-m 🎙️ Xiuning Le MD PhD Hidehito HORINOUCHI 📌Poster Bd135a, Abstr TPS 8663 🔢NCT06706076 OncoAlert ASCO EGFR Resisters LARVOL meetings.asco.org/2025-asco-annu…

What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72

REZILIENT1; Zipalertinib in EGFR ex20ins; 100mg po bd; active but I feel a bit underwhelmed. Impressed by activity in previously treated with targeted Tx. #ASCO25

x.com/i/article/1929…

🔥BREAKING‼️ NEJM 🆙 ✅DeLLphi-304: Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy 🎯Tarlatamab vs chemo 🎯mOS 13.6 vs. 8.3m 🎯OS HR 0.60 (95%CI 0.47-0.77) 🎙️ Giannis Mountzios 🔜 #ASCO25 #LCMS, ORAL, LocoReg/SCLC OncoAlert LARVOL nejm.org/doi/full/10.10…

#ASCO25 🫁Lung Cancer Orals: #CM816 Neoadj chemoNivo x 3 cycles 🎙️Patrick Forde 🔹5 yr OS 65% vs 55% (HR 0.72) 🔹 5yr EFS of those with pCR: 95% ⬆️ OS in ctDNA clearance 👉🏽This trial reinforces the notion that less preop chemo (3 cycles)!may be enough and perioperative

It seems we are in a bit of a data quagmire. I often get asked how to choose between neoadjuvant versus perioperative immunotherapy and right now there aren’t many great answers, but for what it’s worth, here’s my general perspective… #ASCO25

🔄#ASCO25 REVIEW🔁 ☑️#LCSM Oral, LocReg/SCLC 🔥IMforte: Lurbinectedin + atezolizumab as 1L maintenance Tx in pts with ES-SCLC 🎙️ Luis Paz-Ares 🎯Positive PFS & OS 🎯PFS HR 0.54 (0.43-0.67), OS 0.73 (0.57-0.95) OncoAlert ASCO LARVOL meetings.asco.org/2025-asco-annu…

x.com/i/article/1931…

TOMORROW: The BTOG #ASCO25 highlights webinar! 🏥 What’s changing in UK thoracic oncology? 🎤 Hear directly from UK experts reviewing top presentations. 🖥️ Free for BTOG members ⏰ 18:00-19:15 | 🔗 btog.org/asco-update-we… #LCSM #LungCancer Tom Newsom-Davis DrTanyaAhmad

Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study - European Journal of Cancer ejcancer.com/article/S0959-… Jarushka Naidoo

Qx raise about role of ADCs in NSCLC. Data in NSCLC and AGA🧬most in mEGFR at osimertinib. but should be applied as monotherapy? With osimertinib? Some data in NSCLC with other AGA but no intracranial data. There is a room for improvement. We need to define the population

Just published - Confirmation of a novel risk marker for early stage NSCLC, thanks for a great cooperation! #lcsm The Lancet Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lu... sciencedirect.com/science/articl…

“17,000 children killed…Silence from the world”

Activating mutations in EGFR gene has revolutionized management of #LungCancer, enabling development of TKIs. New review on strategies to optimize treatment: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… Alfredo Addeo MD Maxime Borgeaud Timothée Olivier, MD Jair Bar Kaushal Parikh Jill Feldman Xiuning Le MD PhD OncoAlert

NCDB study of pts who survive >5 years in 🫁mesothelioma. ➡️Overall 9.4% of MPM pts, many without surgical resection. Pts who are offered surgery and DECLINE have same survival as those who undergo surgery. Real world KM curves look just like MARS2. sciencedirect.com/science/articl…

The wasted cost of track and trace would have paid for full pay restoration for doctors for the next 37 years.

Pulmonary sarcomatoid carcinoma is a rare NSCLC histology that every thoracic oncologist has or will face in their practice. In this study led by Dr. Lingzhi Hong & Natalie Vokes MD Anderson Cancer Center, we characterized features & outcomes of patients w/ these tumors jto.org/article/S1556-…